CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 113 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $125,660,422 | +3356.0% | 4,225,300 | +1766.3% | 0.37% | +3236.4% |
| Q1 2023 | $3,635,984 | -85.4% | 226,400 | -83.4% | 0.01% | -87.1% |
| Q4 2022 | $24,906,300 | -3.2% | 1,361,000 | +3.9% | 0.08% | -17.5% |
| Q3 2022 | $25,732,000 | +3.5% | 1,310,200 | -1.7% | 0.10% | -1.9% |
| Q2 2022 | $24,857,000 | -6.1% | 1,332,800 | +10.5% | 0.10% | 0.0% |
| Q1 2022 | $26,479,000 | -15.6% | 1,206,338 | +9.2% | 0.10% | -16.0% |
| Q4 2021 | $31,378,000 | +231.4% | 1,104,476 | +145.5% | 0.12% | +197.6% |
| Q3 2021 | $9,468,000 | -29.1% | 449,800 | -36.5% | 0.04% | -30.0% |
| Q2 2021 | $13,348,000 | -31.5% | 708,133 | -44.5% | 0.06% | -34.1% |
| Q1 2021 | $19,482,000 | +12.7% | 1,275,000 | +4.1% | 0.09% | +8.3% |
| Q4 2020 | $17,285,000 | +115.4% | 1,225,003 | +139.3% | 0.08% | +104.9% |
| Q3 2020 | $8,023,000 | +16.0% | 511,988 | +29.7% | 0.04% | -8.9% |
| Q2 2020 | $6,917,000 | +713.8% | 394,832 | +1065.9% | 0.04% | +1025.0% |
| Q4 2019 | $850,000 | -57.2% | 33,865 | -74.3% | 0.00% | -66.7% |
| Q3 2019 | $1,985,000 | – | 132,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |